Metastrict

Challenge

Current cancer therapies insufficiently address metastasis, particularly in colorectal cancer. Key metastatic drivers (MACC1, S100A4) are associated with poor survival when highly expressed, yet remain untargeted by existing therapies.

Solution

Metastrict is developing a novel metastasis inhibitor MSt-001 (E12):

Novel small-molecule inhibitor to block metastasis at its source by preventing the expression of key drivers MACC1 & S100A4
Addresses migration and chemotherapy resistance at the transcriptional level in metastatic colorectal cancer
More fundamental and durable approach than downstream, post-translational interventions
Biomarker-driven, targets resistance and metastasis formation at its core